Biopharma Market Intelligence

Enabling confident decisions

One-Stop-Platform for all Data-Driven Insights

Confident decisions begin with access to the right information

Get Combo Product
At Attractive Price

Have all in one with complete Market Research Insights & data
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/audience-applauding-speaker-after-conference-presentation-1-1.jpg

Unrivaled Audience

We conduct research with a qualified audience in our database of 60,000+ life science specialists. Your queries will be answered by key executives, department heads, and functional leaders from the countries and profiles of your choice.

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/businessman-touching-tip-bar-chart-2.jpg

In-Depth Reach

IMAPAC has served the biopharmaceutical sector for a decade. It is the only company to have provided support to professionals in various fields of biologics and biosimilars across the biopharmaceutical markets.

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/confident-call-center-operator-talking-with-client.jpg

Service You Can Rely On

The markets never rest, and neither do we. Our global support team is available around the clock via phone, email, or chat to help with all aspects of the Market Intelligence platform.

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/Product-Banner-1-Biopharma-Trackers-Option2.jpg

Biopharma Trackers

Our quick-view analytics tool will empower the global biopharmaceutical industry with informed decisions. Access comprehensive, validated data in a user-friendly manner, all here in a single click.

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/Product-Banner-2-Market-reports-Option2.jpg

Market Reports

We provide one-of-a-kind and ready-to-use reports to meet the changing needs of businesses. IMAPAC’s market reports help organizations gain accurate market intelligence in a short span of time at competitive rates.

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/Product-Banner-3-Custom-Research.jpg

Custom Research

Whether you are a market leader, market defender or market explorer, based on your objectives and budget, you may utilize a service or opt for various services combined in a customized package.

IMAPACMarket intelligence data acquisition
& research methodology

  • Live discussions with experts through IMAPAC’s niche conferences
  • Live-polls, surveys, technical focused webcasts/webinars
  • Research interviews with C-Levels & Scientists
  • Company websites, press releases, regulatory and government platforms
  • Market surveillance, compilation, trend-analysis of the industry
  • Data analysis and Interpretation
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-9.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-process-1.jpg
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-8.png

MARKET INTELLIGENCEEnabling Confident Decisions

Extensive biopharmaceutical market information now available at your fingertips. Brought to you by our team of analysts; fully customizable to your requirements.

Growth and Opportunities

Discover opportunities and potential partnerships in the market by identifying the high growth or niche segments.

Competitive Intelligence

Compare and analyse new potential markets, competitive developments such as future expansions, agreements, new product launches, and acquisitions in the global biopharmaceutical market.

Decision Support

Make informed business decisions based on overall insights and company-wise in-depth data - all in a single platform.

Validated Information

validated, and curated Information to support your team in strategic development, presenting the right data and analytics.

Follow Latest Trends

Take your company to the next level, with up-to-date information on the current trends and emerging technologies.

Strong APAC Focus

Asia-Pacific biopharma market is expected to see burgeoning grow in the next 5 to 10 and IMAPAC has strong connections with companies and experts across APAC.
bt_bb_section_bottom_section_coverage_image

Market Intelligence
Enabling Confident Decisions

Extensive biopharmaceutical market information now available at your fingertips. Brought to you by our team of analysts; fully customizable to your requirements.
Growth and Opportunities
Discover opportunities and potential partnerships in the market by identifying the high growth or niche segments.
Competitive Intelligence
Compare and analyze new potential markets, competitive developments such as future expansions, agreements, new product launches, and acquisitions in the global biopharmaceutical market.
Decision Support
Make informed business decisions based on overall insights and company-wise in-depth data - all in a single platform.
Validated Information
validated, and curated Information to support your team in strategic development, presenting the right data and analytics.
Follow Latest Trends
Take your company to the next level, with up-to-date information on the current trends and emerging technologies.
Strong APAC Focus
Asia-Pacific biopharma market is expected to see burgeoning grow in the next 5 to 10 and IMAPAC has strong connections with companies and experts across APAC.
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-dotted-separator.png

Our Clients

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/AGC-Bioloigcs-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/bioengineering-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/BD-biosciences-logo-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/biorad.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/charles-river.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/chime-BIOLOGICS.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/pall-biotech.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/sciex.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/west-logo.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/Gen-Script.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/marken-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/06/organo.png
Amwerk
Codiqa
Urbanist
Estato
California
Addison
Applauz
Bello
Berg
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png

Delivering positive change

bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image

Great client stories

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-7.png
We have worked on custom research projects with IMAPAC and highly impressed with their project approach and research quality. We were able to expand our customer base through this project. The team was extremely professional and proactive in providing timely responses to all our queries
Biologics Technology Solution Provider
Associate Director, Life Sciences
Project helped us access the crucial insights on the companies of our interest area. We successfully identified potential leads in the selected market through their service. We are happy with the services and would definitely be working with them again in the future. Great experience!
Lifescience Flow Cytometry and Reagents Service Provider
Head of Strategy
We utilized IMAPAC’S market intelligence and primary research services to understand our customer’s evolving requirements and preferences. The insights were very detailed and we have been using it to make strategic decisions. Very impressed with the hard work and great efforts put by the team to deliver on the commitments. We will partner again for some more exciting projects.
Global Analytics Solution Provider
Manager- Life Science & Clinical Diagnostic
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image

News & Blogs

While our leaders represent a vast array of expertise and perspectives, all are committed to doing what’s best for our clients and our people in a way that is unmatched by other firms.
Medigen applies for Australian vaccine approval
Excerpt Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine. Article Summary Medigen Vaccine Biologics Corp applied to Australian medicines regulator for provisional approval of the COVID-19 vaccine and has delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say...
July 6, 2022
Prestige Biopharma announces International Non-proprietary Name for PBP1510
Excerpt Prestige Biopharma Limited, announced that its first-in-class antibody PBP1510 has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’ and was placed on the INN Recommended List by the World Health Organization (WHO). Article Summary Prestige Biopharma Limited first-in-class antibody has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’. INN-Ulenistamab, which is also known as...
July 6, 2022
WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
Excerpt WuXi Biologics launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. Article Summary Wuxi Biologics, a global CRDMO service company, recently opened its DP5 facility in Wuxi, China. The facility is the ninth active facility in WuXi Biologics’ global network.   A continuous and steady isolator filling system...
July 6, 2022
Astellas Announces the Opening of Its New Gene Therapy Manufacturing Facility in North Carolina
Astellas Pharma Inc has announced the opening of a new late stage clinical and commercial manufacturing facility in Sanford, North Carolina, US. The facility will allow the company to expand its resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope. Article Summary The new 135,000 square-foot state-of-the-art...
July 6, 2022
Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs has accelerated the plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer. Article Summary Planning has begun on a massive...
July 6, 2022
Prescient Therapeutics Unveils its New Cell Therapy Platform – CellPryme-M
A clinical-stage oncology company Prescient Therapeutics (PTX) has launched its second cell therapy platform, CellPryme-M, which produces superior cells with greater cancer killing activity. This platform opens commercial opportunities for the company to incorporate it into third-party manufacturing processes. Article Summary PTX has developed this new platform technology in association with its research partner, Peter...
July 6, 2022
Tessa Therapeutics Closes a US$126 million Series A financing Round
Article Summary Tessa Therapeutics Ltd has announced the close of a US$126 million Series A financing round. The funding was led by Polaris Partners and existing investors, including Temasek, EDBI, Heliconia Capital and Heritas Capital. In conjunction with the financing, Amy Schulman and Darren Carroll, Managing Partners at Polaris Partners, have joined Tessa’s Board of...
July 6, 2022
The European Investment Bank (EIB) has provided €75 million to the Institut Pasteur de Dakar for the construction of a new vaccine manufacturing facility.
Excerpt Large-scale funding for the Institut Pasteur de Dakar’s new vaccine manufacturing facility, a leader in the area in Africa. The facility, which would produce up to 300 million doses per year against COVID-19 and other endemic diseases, is projected to considerably reduce Africa’s reliance on imported vaccines and support equal access to medicines. This...
July 6, 2022
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
Excerpt GSK will pay $2.1 billion up front and up to $1.2 billion in development milestone payments. The proposed acquisition will give the company access to a next-generation 24-valent pneumococcal vaccine candidate in phase II development as well as MAPSTM technology, which is extremely innovative. Encourages the development of a diverse portfolio of novel vaccines...
July 6, 2022
World Bank Support for Country Access to COVID-19 Vaccines
Excerpt The World Bank has approved $9.5 billion in operations to assist vaccination rollout in 77 countries as of June 15, 2022. Article Summary The World Bank Group is collaborating with partners on the world’s largest vaccine programme to combat the COVID-19 pandemic. The World Bank’s Board of Executive Directors adopted a $6 billion Global...
July 6, 2022
Nippon Express Launches Ultra-low Temperature-controlled Logistics Service for Pharmaceutical Industry
Excerpt: Nippon Express Co., Ltd. (hereinafter “Nippon Express”), a group company of Nippon Express Holdings, Inc., launched on May 30 a logistics service capable of handling goods requiring ultra-low temperatures (-20 C to -85 C) for the pharmaceutical industry.   Article Summary: As a priority approach for the core business growth strategy outlined in the...
July 6, 2022
Samsung Biologics to build first overseas factory in US
Excerpt: Samsung Biologics CEO John Rim said Monday the US states of California, North Carolina, Washington and Texas are the strongest candidates the South Korean contract manufacturing organization is considering for its first overseas production facility.   Article Summary: Pointing out that some of the US’ major bio clusters are located in those four states,...
July 6, 2022
GXO Logistics to open warehouse for pharmaceutical sector
Excerpt: Logistics provider GXO plans to open a 20,000m2  warehouse dedicated to the pharmaceutical sector in Caleppio di Settala in Milan, Italy, by the end of June 2022. Article Summary: The location was chosen for its proximity to major surface transportation arteries to help enable pharmaceutical companies to meet the stringent lead times required for...
July 6, 2022
US drug supply chain alternative to China might run through Canada, Latin America
Excerpt: Centre for Strategic and International Studies panellists from Canada, Mexico, Brazil and Colombia discuss speeding pharmaceutical production and trade with US About 80 per cent of all fine chemicals come from China, according to one estimate, leading to a medical supply chain vulnerability   Article Summary: Representatives of Canada and three Latin American nations...
July 6, 2022
Pfizer and Valneva enter into an equity subscription agreement and update the terms of the collaboration agreement for Lyme disease vaccine candidate VLA15.
Excerpt Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022   Article Summary Valneva announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As part of the Equity Subscription...
July 6, 2022
ABVC Biopharma Submit Phase II Study to the HREC
Excerpt ABVC Biopharma, Inc. a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HREC). Article Summary If the submission is received, HREC approval will lead to a Clinical Trial Notification (CTN) submission to...
July 6, 2022
BioCina COVID-19 Vaccine to be Manufactured in Adelaide as the Company Expands CDMO Service
Excerpt The new BioCina vaccine is being manufactured in an Adelaide facility purchased by the Bridgewest group in 2020 from Pfizer, maker of a successful Covid-19 vaccine – though Pfizer’s vaccine targets only the original strain of the disease. Article Summary The vaccine is claimed to be easily adapted to new variants of Covid-19, making...
July 6, 2022
Impressive Trial Results for Propanc Biopharma with Novel Cancer Treatment
Excerpt Victoria’s Propanc Biopharma Inc. , a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the results from a small trial of just 18 rectal cancer patients in complete remission using an immunotherapy called dostarlimab are “impressive,” whilst acknowledging there’s more work to be done.  Article Summary...
July 6, 2022
Medigen Seeks Therapeutic Goods Administration (TGA) Approval for COVID-19 Vaccine
Excerpt Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine, the pharmaceutical company said in a filing with the Taipei Exchange yesterday. Article Summary The company yesterday delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say when the regulator...
July 6, 2022
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png

Conventions

Don't need to look very far to get a better perspective on your business!

bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image

Connections

0123456789001234567890012345678900123456789001234567890

Life Science Conferences

012345678900123456789001234567890

Clients

0123456789001234567890012345678900123456789001234567890

Countries

012345678900123456789001234567890

Children Sent to School

01234567890012345678900123456789001234567890
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image